OctoPlus to present at London Biotech Investment Forum
OctoPlus N.V. (Euronext: OCTO), the drug delivery and development
company, announces today that its CEO will present at the 3rd Annual
London Biotech Investment Forum in London this week.
Joost Holthuis, Chief Executive Officer, will present on Friday, 20
April at 11:35 AM BST.
For further information, please contact:
Rianne Roukema, Corporate Communications: +31 (71) 524 4044
About OctoPlus
OctoPlus N.V. is a product-oriented biopharmaceutical company
committed to the development of improved pharmaceutical products that
are based on its proprietary drug delivery technologies and have
fewer side effects, improved patient convenience and a better
efficacy/safety balance than existing therapies. Rather than seeking
to discover novel drug candidates through early stage research
activities, OctoPlus focuses on the development of long-acting,
controlled release versions of known protein therapeutics and other
drugs.
OctoPlus is also a leading provider of advanced drug formulation and
clinical scale manufacturing services to the pharmaceutical and
biotechnology industry, with a focus on difficult to formulate active
pharmaceutical ingredients in injectable formulations. The earnings
and expertise that OctoPlus derives from rendering formulation and
manufacturing services help to support its own drug development
programs.
OctoPlus is listed on Euronext Amsterdam under the symbol OCTO. For
more information about OctoPlus, please visit our website
www.octoplus.nl.
This document may contain certain forward-looking statements relating
to the business, financial performance and results of OctoPlus N.V.
and the industry in which it operates. These statements are based on
OctoPlus N.V.'s current plans, estimates and projections, as well as
its expectations of external conditions and events. In particular the
words "expect", "anticipate", "predict", "estimate", "project",
"plan", "may", "should", "would", "will", "intend", "believe" and
similar expressions are intended to identify forward-looking
statements. We caution investors that a number of important factors,
and the inherent risks and uncertainties that such statements
involve, could cause actual results or outcomes to differ materially
from those expressed in any forward-looking statements. In the event
of any inconsistency between an English version and a Dutch version
of this document, the English version will prevail over the Dutch
version.
